Newsroom | 5155 results

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp...

MADISON, Wis.--(BUSINESS WIRE)--Navitus today released its 10th annual Drug Trend Report, “Clarity for Action,” the company’s flagship annual analysis of prescription drug cost trends. The report details how utilization growth and therapeutic innovation drove prescription drug costs in 2025 and outlines clear actions for health plans and plan sponsors to counter accelerating pressure. Across the Navitus commercial book of business, net prescription drug costs increased 8.4%, up from 7% in 2024,...

GOTHENBURG, Svezia e BURGDORF, Svizzera--(BUSINESS WIRE)--Glooko, Inc. e mylife Diabetes Care oggi hanno reso noto un accordo per ampliare ulteriormente la loro collaborazione, che prevede che Glooko serva da piattaforma primaria per la gestione dei dati di mylife Diabetes Care per i prodotti mylife. Questa nuova iniziativa si basa sulla stretta collaborazione ben consolidata tra le due aziende, garantendo la continuità delle modalità di accesso ai dati da parte dei pazienti e dei professionist...

GÖTEBORG, Zweden & BURGDORF, Zwitserland--(BUSINESS WIRE)--Glooko, Inc. en mylife Diabetes Care hebben vandaag een overeenkomst aangekondigd om hun samenwerking verder uit te breiden. Glooko zal fungeren als het primaire databeheerplatform van mylife Diabetes Care voor mylife-producten. Deze volgende stap bouwt voort op het sterke, reeds lang bestaande samenwerkingsverband tussen de twee bedrijven en zorgt voor continuïteit in de manier waarop zorgprofessionals en patiënten toegang krijgen tot...

GÖTEBORG, Suède et BURGDORF, Suisse--(BUSINESS WIRE)--Glooko, Inc. et mylife Diabetes Care ont annoncé aujourd’hui la conclusion d’un accord visant à étendre leur partenariat. Glooko deviendra ainsi la plateforme principale de gestion des données pour les produits mylife de mylife Diabetes Care. Cette nouvelle étape s’inscrit dans la continuité d’une collaboration solide et bien établie entre les deux entreprises, garantissant aux professionnels de santé et aux patients un accès harmonisé aux d...

GOTEMBURGO (Suecia) y BURGDORF (Suiza)--(BUSINESS WIRE)--Glooko, Inc. y mylife Diabetes Care anunciaron hoy un acuerdo para ampliar aún más su alianza, según la cual Glooko será la principal plataforma de gestión de datos de mylife Diabetes Care para los productos mylife. Este siguiente paso se inscribe en el marco de una colaboración sólida y bien establecida entre las dos empresas, para garantizar una continuidad en la forma en que los profesionales de la salud y sus pacientes acceden a los d...

GÖTEBORG, Schweden & BURGDORF, Schweiz--(BUSINESS WIRE)--Glooko, Inc. und mylife Diabetes Care gaben heute eine Vereinbarung zur weiteren Ausweitung ihrer Partnerschaft bekannt, in deren Rahmen Glooko als primäre Datenmanagement-Plattform von mylife Diabetes Care für mylife-Produkte fungieren wird. Dieser nächste Schritt baut auf der starken, gut etablierten Zusammenarbeit zwischen den beiden Unternehmen auf und gewährleistet Kontinuität beim Zugriff von medizinischem Fachpersonal und Patienten...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today reported its first quarter 2026 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. “This quarter, we continued to build on our developmental and clinical acc...

DENVER--(BUSINESS WIRE)--Virta Health, the leader in reversing metabolic disease, today announced new peer-reviewed research published in Endocrine Research demonstrating that its nutrition-based metabolic care model delivers broad and sustained reductions in inflammatory markers in adults with type 2 diabetes (T2D). In the study, 19 of 21 inflammatory and immune markers significantly improved after one year of treatment, with improvements largely maintained through two years. This nutrition-ba...

KONTICH, Belgium--(BUSINESS WIRE)--Flen Health Pharma NV, a Belgium-based biopharmaceutical company with more than 25 years of experience in wound and skin healing solutions, today announced that the U.S. Food and Drug Administration (FDA) has provided positive written feedback following an INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs) meeting regarding VES gel, a novel biologic designed to accelerate healing in chronic diabetic foot ulcers (DFUs). The FDA’s...